---
title: "Lyell Gains Buy Rating on Leadership in CD19/20 CAR-T and Ronde-cel Progress; Analyst Reiterates $45 Price Target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285536200.md"
description: "Mitchell Kapoor from H.C. Wainwright has reiterated a Buy rating on Lyell Immunopharma with a price target of $45. The rating is based on Lyell's leadership in the CD19/20 CAR-T space and the progress of its lead asset, ronde-cel. Kapoor highlights the company's pivotal LBCL programs and strong cash balance, which extends its runway into 2027. Needham also maintains a Buy rating with a $44 price target."
datetime: "2026-05-07T11:05:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285536200.md)
  - [en](https://longbridge.com/en/news/285536200.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285536200.md)
---

# Lyell Gains Buy Rating on Leadership in CD19/20 CAR-T and Ronde-cel Progress; Analyst Reiterates $45 Price Target

In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Lyell Immunopharma, with a price target of $45.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Mitchell Kapoor has given his Buy rating due to a combination of factors tied to Lyell’s leadership in the emerging CD19/20 CAR‑T space and the progress of its lead asset, ronde‑cel. He sees Lyell as the most attractive listed vehicle for exposure to this category, supported by two pivotal LBCL programs (PiNACLE in 3L+ and PiNACLE‑H2H in 2L) that are advancing toward key data in 2026–2027 and a planned BLA filing in 2027.

He also highlights ronde‑cel’s strong efficacy and durability in high‑risk LBCL populations, alongside a safety profile amenable to outpatient use, which he believes differentiates Lyell versus other CD19 players. In addition, he notes that Lyell’s $261M cash balance, bolstered by its recent private placement, extends the runway into 3Q27 and should cover several major data readouts, while the head‑to‑head 2L trial versus axi‑cel and liso‑cel offers a clear opportunity to demonstrate clinical superiority and secure commercial leadership, supporting his unchanged $45 price target.

In another report released today, Needham also maintained a Buy rating on the stock with a $44.00 price target.

### Related Stocks

- [LYEL.US](https://longbridge.com/en/quote/LYEL.US.md)

## Related News & Research

- [Lyell Immunopharma (LYEL) to Release Quarterly Earnings on Tuesday](https://longbridge.com/en/news/285244886.md)
- [Lyell Immunopharma, Inc. (NASDAQ:LYEL) Receives Consensus Recommendation of "Hold" from Analysts](https://longbridge.com/en/news/282344009.md)
- [UBS Sticks to Their Buy Rating for Aptiv (APTV)](https://longbridge.com/en/news/286947173.md)
- [Jefferies Reaffirms Their Buy Rating on Devon Energy (DVN)](https://longbridge.com/en/news/286728558.md)
- [SanDisk stock slips: why this analyst still sees a 50% upside](https://longbridge.com/en/news/286938149.md)